Voyager Therapeutics interim CSO Glenn Pierce resigns as planned, enters consulting agreement; shareholders re-elect him

Voyager Therapeutics, Inc.

Glenn Pierce resigned as Interim CSO effective June 2, 2022, after serving in the role since June 2021 on a part-time basis.
On June 6, Pierce signed a consulting agreement with Voyager capped at $120,000, valid until June 5, 2023, for transition services.
At the June 6 annual meeting, Pierce was re-elected as Class I director with 21,014,996 votes (88.9% of votes cast).
Shareholders approved say-on-pay with 23,447,480 votes and ratified Ernst & Young as auditor with 30,505,725 votes.
Todd Carter, SVP Research, assumed increased R&D responsibilities starting June 3, reporting to CEO; search for a CSO is underway.

item 5.02 item 5.07 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed (interim)

Glenn Pierce

Interim Chief Scientific Officer

VYGR · Voyager Therapeutics, Inc.

Effective: 2022-06-02
Filed: June 7, 2022, 7:59 PM ET

On June 2, 2022, Glenn Pierce, M.D., Ph.D. provided notice to Voyager Therapeutics, Inc. (“Voyager”) of his resignation as Interim Chief Scientific Officer, effective immediately (the “Pierce Transition”).

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Glenn Pierce resigned as Interim Chief Scientific Officer at Voyager Therapeutics, Inc..

Action: resigned
Role: Interim Chief Scientific Officer

Exact text from the filing

On June 2, 2022, Glenn Pierce, M.D., Ph.D. provided notice to Voyager Therapeutics, Inc. (“Voyager”) of his resignation as Interim Chief Scientific Officer, effective immediately (the “Pierce Transition”).

View on SEC.gov

Voyager Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-068958

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.